Our IWMF experts will share an update on the status of existing COVID-19 vaccines and others in development. This interactive LIVE question and answer session will explain side effects and recommendations for WM patients.
After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.
What are the treatments for Waldenstrom macroglobulinemia and what's in the pipeline? Can Waldenstrom patients plan for a higher quality of life? Dr. Jorge Castillo, Clinical Director, Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, presents an overview of his presentation at the 2020 IWMF with Patient Power co-founder Andrew Schorr.
Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast.
Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos present a summary of trial findings and details regarding various BTK inhibitors, including ibrutinib, zanubrutinib, acalabrutinib, tirabrutinib, LOXO-305, etc.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). The Prescription Drug User Fee Act (PDUFA) target action date is October 18, 2021.
December 21, 2020: Dr. Jorge Castillo walks us through immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis–and finally, how to talk to patients about them.
Dear IMS Member: We hope you are well during these difficult times. As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance.
On January 27, Dana Farber held a webinar to review the information regarding COVID-19 vaccinations for patients. Catherine Flynn (from the Bing Center Clinic) shares the following highlights from the webinar. Note, the entire webinar was recorded and posted to Facebook, using the following link:
Based on the latest guidance we have received from the state of Massachusetts, we expect Dana-Farber's supply of COVID-19 vaccine for patients to be very limited in February and perhaps longer. We are working hard to place special focus on getting vaccines to our most at-risk patients, in compliance with the state's rollout guidelines, as we receive allotments of the vaccine.